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Hepatitis C viral clearance in an
intravenous drug-using cohort in
the Dublin area
ABSTRACT
Background The rate of spontaneous HCV viral clearance is reported as 20-25%
but recent data indicate a higher frequency in some cohorts. The rate of
spontaneous clearance in intravenous drug users has not been reported
in an Irish setting.
Aims To determine the rate of spontaneous hepatitis C viral clearance and
genotype in an Irish intravenous drug-using cohort.
Methods Drug users attending five drug treatment clinics in the Dublin were
investigated. Data were prospectively recorded from January 1997 to
June 2001 and follow-up testing completed in 2003. There were 496
HCV antibody positive patients identified and assessed for HCV RNA
clearance. All were HIV and hepatitis B negative, 68.8% were male.
Results HCV RNA negativity (viral clearance) was documented in 38% of
patients. Viral clearance was 47.4% in females and 34.5% in males
(p=ooo.6). Clearance was independent of age or duration of intravenous
drug use. Viral clearance as defined as two negative consecutive HCV
RNA tests, a minimum of one year apart, was sustained in 82.2% at two-
year follow-up, giving an overall viral clearance of 31.1%. HCV genotype 1
and 3 were most commonly identified at 48.8% and 48.5% respectively in
those with chronic infection.
Conclusions Spontaneous HCV viral clearance occurs at a higher frequency than
previously reported. Genotype 1 and 3 are commonest in the patient cohort.
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INTRODUCTION
In the past decade, hepatitis C has been
identified as the major cause of non-A, non-
B hepatitis in the developed world.'3 Risk
factors include intravenous drug use with
needle sharing, exposure to contaminated
blood or blood products, high-risk sexual
contact or household contact and low
socio-economic status.4 9 Acute infection is
frequently sub-clinical or asymptomatic but
chronic infection can lead to cirrhosis and
hepatocellular carcinoma.9"
Disease progression has been linked to
excess alcohol consumption, duration of
intravenous drug use, older age at infection
and co-infection with other viruses.12 At least
six different genotypes and more than 90
subtypes of hepatitis C exist worldwide.'3
Disease outcome and treatment response
IRISH JOURNAL OF MEDICAL SCIENCE • VOLUME 174 • NUMBER 1 37
HEPATITIS C VIRAL CLEARANCE IN AN INTRAVENOUS DRUG-USING COHORT IN THE DUBLIN AC
may differ according to genotype thus
genotyping is warranted among patients who
are being considered for treatment.
Currently, third-generation enzyme
immunoassays (EIA-2 and EIA-3) for hepatitis
C antibody (anti-HCV) are the most widely
used screening tests for the diagnosis of
HCV infection, confirmed by recombinant
immounoblot assay (RIBA).'3 These tests
however do not distinguish between acute,
chronic or resolved infection. In the event of
a positive antibody test, confirmatory testing
of HCV RNA in serum by polymerase chain
reaction (PCR) is seen as the gold standard for
the diagnosis of active HCV infection.14
In Ireland, two main patient cohorts who
have been exposed to hepatitis C have been
identified. The first group are recipients of
blood or blood products contaminated with
hepatitis C between 1970 and i994.8-9The
second group are intravenous drug users
(IVDUs). Retrospective analysis has shown
that the overall seroprevalence for hepatitis C
in this group is 52-81 per cent.5-15
In the greater Dublin area there are an
estimated 13,000 intravenous drug users,
the majority of whom are in treatment
in the HIV and addiction services.16 Once
attending these clinics, all IVDUs are actively
encouraged to avail themselves of viral
testing for hepatitis A, hepatitis B, hepatitis C
and HIV and vaccination against hepatitis A
and B, where appropriate. In 1997, designated
hepatitis C review clinics were introduced
in the main drug treatment units in the city
to offer drug-using clients HCV RNA testing
and assessment of their drug stability and
alcohol consumption.This report highlights
preliminary data from these hepatitis
C review clinics seven years after their
inception.
METHODS
Data were prospectively recorded on the
496 hepatitis C antibody positive patients
who presented for hepatitis C testing in the
drug treatment clinics in the Dublin area
from January 1997 to June 2001. Referrals to
the clinics were made by psychiatrists and
general practitioners specialising in drug
abuse and were independent of clinical
fitness or drug stability. Patients had not
seroconverted for hepatitis B or HIV as
confirmed by serological testing.
For each patient, the following data
were obtained: age, sex and year of
commencement of intravenous drug use. HCV
RNA status was recorded for each patient by
the Roche Amplicor HCV polymerase chain
reaction method with a laboratory assay cut-
off of 100 copies/ml.'7'8 HCV genotyping was
performed by restriction-fragment-length
polymorphism analysis of sequences in the 5'
non-coding region of Hepatitis C genome.'7'8
Comparative statistics were performed using
Chi squared test and Levene's test for equality
of variances.
RESULTS
Demographic Data
Of those who participated in this study, 68.8%
were male and 31.2% were female. Mean ages
were 28.75 (SD 6.35) for males and 26.11 (SD
5.93) for females (ns). Mean ages of IVDU
initiation for males and females were 20.20
(SD 4.74) and 20.27 (SD 4-43) respectively
(ns). Average duration of IVDU was 9.23 (SD •
5.93) for males and 6.59 (SD 5.72) for females
(p< 0.001).
Viral Data
Of the 496 anti HCV-positive participants in
this study, HCV RNA was not detected in 191.
This results in an initial viral clearance rate
of 38.4%. Sustained viral clearance rate was
31.1%. HCV RNA clearance was more frequent
in females than males X2=746, DFi, p = 0.006
(Table 1). Mean age in the HCV RNA positive
group was 27.7 (SD 6.3) and 27.8 (SD 6.4) in
the HCV negative group (t=0.O4, p=0.97).
Those who gave a history of jaundice were
more likely to clear the virus spontaneously
(12.04%) than those who did not clear the
virus (7.87%) X2=6.77 DFi,p=0.006. Viral
clearance was not associated with duration of
intravenous drug use (Table 1).
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Of the 299 PCR positive samples in which
genotyping data was available (98%),
genotype l was observed in 146 (48.8%),
genotype 2 in 6 (2.%), genotype 3 in 145(48.5%)
and genotype 4 in 2 (0.7%). Genotypes 5
and 6 were not identified in this patient
cohort. Measurement of genotype I or 3 was
independent of sex (Table 2).
Viral clearance data at two-year follow-up
showed that of a total of 127(66.5%) originally
PCR negative patients who were retested, 21
(17.2%) were now PCR positive.
DISCUSSION
In this study of IVDUs in the Dublin area,
thirty eight per cent of clients had no evidence
of hepatitis C virus as assessed by PCR assay.
Viral clearance was commoner in females
and in those with a history of jaundice at
diagnosis but was independent of length of
time since initial intravenous drug use. In
those who were PCR positive, genotypes 1 and
3 were most commonly noted.
Villano et al have reported a 14 per cent level
of viral clearance in a cohort of 43 people
with a history of illicit drug use whom they
followed over an eight-year period.19 Viral
clearance was more likely to be associated
with ancestry and a history of jaundice.19
Similar data have also been reported in
the U.S.A.20 In a study of 258 patients, viral
clearance was observed in 17 per cent of
IVDUs. A history of parenteral exposure and a
long drug-free interval were both associated
with an increased likelihood of persistent
viraemia. In a further study of 13 hepatitis C
positive IVDUs, apparent viral clearance was
observed in 38 per cent.21 In an Irish study of
a large cohort of women who tested positive
for hepatitis C following contaminated anti-D
immune globulin, a viral clearance rate of 45
per cent was reported.9
In this study, viral clearance, as demonstrated
by the percentage of PCR-negative samples
Table 1
CHARACTERISTICS OF PARTICIPANTS ACCORDING TO
PATTERN OF VIRAEMIA
Characteristic
Sex, n(%)
Male
female
Mean age (SD) at
time of initial
HCV RNA testing
Duration of IVDU
In years (SD)
Viral Clearance
(n = 191)
118 (34-5%)
73 (474%)
27.8(6.4)
8.8(6.4)
Viral persistence
(n = 305)
224 (65.5%)
81 (52.6%)
27.7(6.3)
8.6(5.9)
P
NS
NS
TABLE 2
CHARACTERISTICS OF PARTICIPANTS ACCORDING TO
PATTERN OF VIRAEMIA
Genotype
Type i, n (%)
Type 2, n (%) :
Type 3, n (%)
Type 4, n (%)
Male
(n=219)
108(49.6%)
5(2.0%)
105(47.9%)
1 (0.5%)
Female
(n=8o)
38 (475%)
1 (1.2%) ^
4O (5O.O%)
1 (1.2%)
* Sample size too small for statistical analysis
P
NS
*
NS
*
in this cohort is also high at 38%. Sustained
viral clearance was also high at 31.1%. It was
not possile to elicit whether the drop in
viral clearance represented reinfection or
reactivation.There was no clinical bias at
referral level in that all patients, irrespective of
clinical well-being, were reviewed. We included
all patients who were hepatitis C positive, as
selecting only patients who were unwell due
to HCV infection may have biased the overall
viral clearence rate, as may be the case in
hospital based Hepatitis C clinic audits. Female
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patients had significantly higher levels of
viral clearance than male patients. A similar
finding was reported by Farrell and from a
study of intravenous drug users in Iceland
but a contrasting finding was reported in
the Dionysos study, which noted that HCV
RNA positivity was higher in females.22'24 Viral
clearance in this study was higher in those
with a history of jaundice at seroconversion,
as was previously noted by Villano et al.19
Viral clearance was independent of duration
of intravenous drug use both for males and
females.This is in contrast with the findings
of Quinn et al in which an association
between persistent viraemia and time since
most recent parenteral exposure was noted.20
Many immunological mechanisms of HCV
viral clearance have been postulated. IL-io
haplotypes, HCV specific T-cell responses
and tumour necrosis factor alpha gene
polymorphism have all been implicated.2527
Immune function may be altered in this IVDU
cohort but a review of this is beyond the
scope of this study.
Genotypes I and 3 diseases were the most
common forms of hepatitis C identified
in this cohort. It has been suggested that
spontaneous clearance of hepatitis C might
be higher in patients with genotype 3
disease than genotype i.28 Genotype data at
seroconversion were not available in
this cohort.
Genotype data would suggest that there
is marked geographic variability. In the
United States, approximately 70 per cent
of hepatitis C-infected persons are infected
with genotype i.29 In England and Wales,
hepatitis C genotypes 1 and 3 are the most
prevalent genotypes in intravenous drug-
abusing patients.30 A similar genotype
pattern was found in Italy, Germany, Iceland
and Spain.^'^lnthis Irish group, genotypes
i and 3 accounted for the majority of cases,
accounting for 48.8% and 48.5% IVDU patient
cohort infected with hepatitis respectively.
Genotypes were independent of sex.
In summary, we report a high rate of viral
clearance in a Dublin intravenous drug-using
cohort attending drug services for treatment.
The cohort size was large and reflected the
Dublin drug community in terms of the
percentage of male to female, the large age
range and durations of intravenous drug
use. In contrast to many published reports
from similar communities in Europe, the rate
of viral clearance was found to be higher in
females than males and independent of age
and duration of intravenous drug use.
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